Researchers at Kazakh National Agrarian Research University engineered an intranasal monoclonal antibody targeting mugwort pollen allergen that effectively prevented hay fever and asthma symptoms in sensitized mice. This approach represents a needle-free, rapid-acting therapy tailored to specific pollen allergens. The findings, published in Frontiers in Immunology, suggest potential for developing similar precision allergy treatments for other common pollens, addressing the growing prevalence of allergic rhinitis and asthma in affected populations.